Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis.

Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. · 2014

Read Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. by Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3986942.txt.

Introduction

Sandra Meyer-Moock and colleagues audit the two standard yardsticks of multiple sclerosis in BMC Neurology in 2014. Trials judge treatments by the Expanded Disability Status Scale, a clinician-rated ladder, and the Multiple Sclerosis Functional Composite, a scored trio of timed tasks. Whether these instruments meet psychometric standards, validity, reliability, and sensitivity to change, decides how much their numbers can be trusted. From 3,860 search hits the team distilled 120 full papers on the scales' measurement properties.

Fifty-four papers assessed the disability scale, twenty-six the composite, and forty both. The disability scale showed documented weaknesses in reliability and in detecting change. The composite's main flaws were practice effects, patients improving by repetition, and quirks of its z-score method. The review gives trialists a candid account of what each endpoint can and cannot support.

Catalog record

CREATORMeyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3986942

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis By Sandra Meyer-Moock, You-Shan Feng, Mathias Maeurer, Franz-Werner Dippel, Thomas Kohlmann Published in: BMC Neurology DOI: 10.1186/1471-2377-14-58 ABSTRACT Background There are a number of instruments that describe severity and progression of multiple sclerosis and they are increasingly used as endpoints to assess the effectiveness of therapeutic interventions. We examined to what extent the psychometric properties of two accepted instruments – EDSS and MSFC – meet methodological standards and the value they have in clinical trials. Methods We conducted a systematic literature search in relevant databases [MEDLINE (PubMed), ISI Web of Science, EMBASE, PsycINFO & PSYNDEX, CINAHL] yielding 3,860 results. Relevant full-text publications were identified using abstract and then full-text reviews, and the literature was reviewed. Results For evaluation of psychometric properties (validity, reliability, sensitivity of change) of EDSS and MSFC, 120 relevant full-text publications were identified, 54 of them assessed the EDSS, 26 the MSFC and 40 included both instruments. The EDSS has some documented weaknesses in reliability and sensitivity to change. The main limitations of the MSFC are learning effects and the z-scores method used to calculate the total score. However, the methodological criterion of validity applies sufficiently for both instruments. For use in clinical studies, we found the EDSS to be preferred as a primary and secondary outcome measure in recent studies (50 EDSS, 9 MSFC). Conclusions Recognizing their strengths and weaknesses, both EDSS and MSFC are suitable to detect the effectiveness of clinical interventions and to monitor disease progression. Almost all publications identify the EDSS as the most widely used tool to measure disease outcomes in clinical trials. Despite some limitations, both instruments are accepted as endpoints and neither are discussed as surrogate parameters in identified publications. A great advantage of the EDSS is its international acceptance (e.g. by EMA) as a primary endpoint in clinical trials and its broad use in trials, enabling cross-study comparisons. BACKGROUND Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that mainly affects young adults. The disease is characterized by the occurrence of relapsing neurological deficits that affect different functional systems of the central nervous system. The majority of patients initially present with a relapsing remitting disease course (RRMS > 80%), however after 10 – 15 years about 60% of these patients show a transition into a secondary progressive disease course (SPMS) that is characterized by a gradual decline of neurological function. In less than 15% of cases, the disease course is progressive from the onset (primary progressive MS, PPMS) [1]. In recent decades, a number of instruments have been developed that describe the clinical severity and the functional deficits in multiple sclerosis. These instruments are increasingly used as an endpoint in clinical trials to assess the effectiveness of therapeutic interventions. The most popular and widely used instrument is the Expanded Disability Status Scale (EDSS) of Kurtzke [2]. The EDSS is a clinician-administered assessment scale evaluating the functional systems of the central nervous system. The EDSS is used to describe disease progression in patients with MS and to assess the effectiveness of therapeutic interventions in clinical trials. It consists of ordinal rating system ranging from 0 (normal neurological status) to 10 (death due to MS) in 0.5 increments interval (when reaching EDSS 1). The lower scale values of the EDSS measure impairments based on the neurological examination, while the upper range of the scale (> EDSS 6) measures handicaps of patients with MS. The determination of EDSS 4 – 6 is heavily dependent on aspects of walking ability. Another important instrument is the Multiple Sclerosis Functional Composite (MSFC) [3], which was developed by the MS Society’s Clinical Assessment Task Force [4] as an additional clinical measure of MS disability progression. The primary goal for creating the MSFC was to improve the standard measure of MS disability for clinical trials and to develop a multidimensional metric of overall MS clinical status [4]. The MSFC is a three-part performance scale for evaluating the degree of impairment in MS patients. It includes the assessment of leg function by moving a short walking distance (“Timed 25-Foot Walk”, T25FT), the assessment of arm function using breadboard test (“9-Hole Peg Test”, 9HPT) and an attention/concentration test to assess cognitive functions (“Paced Auditory Serial Addition test”, PASAT). An integrated MSFC score is calculated using z-scores. There is an ongoing debate about which dimensions to include in the MSFC (e.g. the inclusion of a vision testing) as well as how the reference population affect the standardized scoring (z-scores) of the MSFC [5-13]. In recent years, the MSFC is increasingly used in clinical trials. A number of other instruments are available to assess MS: the Ambulation Index (AI) [14], the Scripps Neurological Rating Scale (SNRS) [15] and the Illness Severity Scale (ISS) [16], the Guy’s Neurological Disability Scale (GNDS) [17] and the Multiple Sclerosis Impairment Scale (MSIS) [18]. Furthermore, the overall Functional Independence Measure (FIM) [19] and the Cambridge Multiple Sclerosis Basic Score (CAMBS) [20] are clinical assessment instruments that could be used to assess MS [21]. Specific instruments for measuring health-related quality of life in MS patients are the Multiple Sclerosis Quality of Life-54 (MSQOL-54) [22] and the Multiple Sclerosis Quality of Life Inventory (MSQLI) [23]. Only a few of these instruments meet the requirements of methodological standards (e.g. validity, reliability, responsiveness), particularly for use in clinical trials. None of these instruments is recognized to use in clinical trials without any restrictions. The aim of this study was to identify strengths and weaknesses of EDSS and MSFC. We investigated to what extent the psychometric properties of the two most important instruments – EDSS and MSFC – meet the methodological standards and what value they have in clinical trials. Although different methodological characteristics of the EDSS are the focus of many studies, a summary and synthesis of the study results is missing. In addition, the importance the MSFC is still a matter of debate and a summary of its methodological characteristics is also missing. We addressed this gap by conducting a systematic literature review to specifically answer the following questions: • Are the instruments suitable to detect the efficacy and/or effectiveness of clinical interventions and to monitor the disease progress? • Do the methodological properties of EDSS and MSFC meet the required standards of objectivity, reliability and validity as applied to instruments for assessment of disease impact in MS? • What is the evidence of the practicality and sensitivity to change of these instruments? • Which methodological shortcomings of EDSS and MSFC must be considered in interpretation of study results? • Which minimally important difference (minimal clinically important difference, MCID) is reported for EDSS and MSFC? METHODS The study was conducted in two phases. First, an exploratory electronic literature search was undertaken to (a) develop and optimize a systematic search strategy and (b) estimate the extent and quality of available studies. Then, a systematic literature search was conducted using the developed search algorithms. The databases MEDLINE (PubMed), ISI Web of Science, EMBASE, PsycINFO and CINAHL & PSYNDEX were systematically searched. Search terms were: Multiple Sclerosis + Expanded Disability Status Scale OR

Read the complete text